Week in Review: Walmart-CVS Partnership Ending, and More Than 6 Million Reported Sick With Influenza This Season

January 18th 2019

This weekly video program provides our readers with an in-depth review of the latest news, medical product approvals, FDA rulings, and more. The Week in Review highlights a Contemporary Clinic article each week, and is a can't miss for the busy healthcare professional.

This weekly video program provides our readers with an in-depth review of the latest news, medical product approvals, FDA rulings, and more. The Week in Review highlights aContemporary Clinicarticle each week, and is a can't miss for the busy healthcare professional.

Nicole Grassno, Host: Hello and welcome to thePharmacy TimesNews Network. I’m Nicole Grassano your host for our Pharmacy Week in Review.

CVS Health officials have said that Walmart has opted to leave the CVS Caremark pharmacy benefit management commercial and Managed Medicaid retail pharmacy networks,Pharmacy Timesreported.

This is because "Walmart requested reimbursement increases that would ultimately result in higher costs for clients and consumers," according to a statement on the CVS website.

CVS Caremark has requested that Walmart continue to fill prescriptions as an in-network participating pharmacy through April 30, 2019.

This transition does not affect Walmart's participation in the CVS Caremark Medicare Part D pharmacy network. In addition, Walmart's Sam's Club division remains in the CVS Caremark pharmacy networks.

Between 6 and 7 million people have been sick with influenza so far during the 2018-2019 season, according to data released on January 11, 2019, from the CDC,Contemporary Clinicreported.

Up to half those who have or had influenza have sought medical care for their illness, and between 69,000 and 84,000 people have been hospitalized from the flu.

These data are derived using the same mathematical model used to generate previous end-of-season estimates, but this is the first time the data are being released during the season, CDC officials said.

Calculations are based on adjusted rates of laboratory-confirmed, influenza-associated hospitalizations collected through a surveillance network that covers about 8.5% of the U.S. population, or about 27 million people.

A new study has identified biological markers that may distinguish between low-risk and intermediate- and high-risk prostate cancer, ultimately helping to guide treatment decisions,Specialty Pharmacy Timesreported.

The study, published inMayo Clinic Proceedings, determined that genetic alterations associated with intermediate- and high-risk prostate cancer may also be present in some cases of low-risk prostate cancers.

More than half of the 200,000 American men diagnosed each year with prostate cancer by biopsy could be considered at low risk of progression to cancer, the researchers wrote.

Men with low-risk cancer are candidates for active surveillance, but some choose surgery to mitigate potential disease progression.

Pharmacists may get more questions about Aleve if their patients have seen a new commercial for the OTC pain reliever.

In the spot, called “Still Thinking,” when comparing brands, a shopper reports that Aleve relieves pain better than Tylenol Extra Strength.

She says the medicine also lasts longer with fewer pills, leading her to purchase Aleve.

For more great coverage and practical information for today’s pharmacist, visit our website and sign up for our Daily eNews. And don’t forget to follow us on Facebook, Twitter, and Instagram.

Thanks for watching our Pharmacy Week in Review. I’m Nicole Grassano at thePharmacy TimesNews Network.

Follow Contemporary Clinic onFacebook,Twitter, andLinkedIn.

Related Content